Search

Your search keyword '"Patient compliance"' showing total 17,100 results
Start Over Descriptor "Patient compliance" Database Gale General OneFile
17,100 results on '"Patient compliance"'

1. AMCP Nexus: The Academy of Managed Care Pharmacy (AMCP) held its fall meeting, called AMCP Nexus, Oct. 14-17 in Las Vegas. Here is some of our coverage of the meeting

Author

Gallagher, Ashley

Subjects
Trospium, Patient compliance, Diflunisal, Drugstores, Managed care plans (Medical care), Adalimumab, Amyloidosis, Fulvestrant, Company business management, Business, Health care industry, Amvuttra (Medication), Humira (Medication)
Abstract

With new drugs in the offing, treatment cost ofATTR-CM is projected to climb By some accounts, spending worldwide on treatment of patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) is projected to [...]

Published
2024

2. Wilms' Tumor - An Audit

Author

Sarin, Yogesh Kumar, Losu, Pute U., and Nangia, Anita

Subjects
Cancer -- Adjuvant treatment, Metastasis, Patient compliance, Radiotherapy, Health
Abstract

Background and Aims: Outcome analysis of patients with Wilms' tumors (WT) is presented. Materials and Methods: A retrospective analysis of 23 children having WT managed by a single surgeon over 3 years (2021-2024) using the International Society of Paediatric Oncology Umbrella protocol was done. Results: The median age at presentation was 36 months; 32 months and 24 months for the unilateral WT (uWT) (n = 19) and bilateral WT (bWT) (n = 4), respectively. M: F ratio was 2.3: 1. WTs were localized in 19 (uWT-16; bWT-3) and metastatic in 4 (uWT-3; bWT-1) patients. Core-needle biopsy was done in 22 patients (26 renal units). Pre-therapy contrast-enhanced computed tomography volumetry (n = 20) showed a median tumor volume of 1023 ml (range: 47-2680 ml). Post-neoadjuvant chemotherapy (NACT) median tumor burden (n = 19) was 612 ml (range 59-3775 ml). Post-NACT, tumor volume decreased in 11/18 patients but increased in seven patients. NACT was avoided in one neonate. Nephroureterectomy (including one with excision of bladder cuff) and nephron-sparing surgery were done in 17 and 10 renal units including 3 with multifocal WT, respectively. Risk stratification was intermediate in 21 and High in 2. Overall staging in 19 uWT included Stage I-7, Stage II-5, Stage III-4, and Stage IV-3 (local staging-stage I in 1 and stage II in 2). Local staging in 8 renal units with bWT was Stage I in 7 and II in 1. One stage IV uWT had bilateral pulmonary metastatectomy. Adjuvant chemotherapy has been completed in 18 patients; two patients are still on adjuvant chemotherapy; flank radiation was administered in six patients. Three patients with synchronous bWT died; two due to acute kidney injury in the immediate postoperative period and one with metastatic disease who had abandoned adjuvant chemotherapy after the 1[sup.st] cycle. Another patient died of a huge metachronous tumor in the contralateral kidney after a year of completion of therapy. One patient had successful multimodality treatment of local relapse with liver metastasis. 1-year overall and event-free survivals are 84 and 76, respectively. Conclusions: Excellent short-term results for localized uWT from a center in a low-middle-income country are reported. Keywords: Adjuvant chemotherapy, event-free survival, histopathology, immunohistochemistry, neoadjuvant chemotherapy, non-Wilms', renal tumors, overall survival, radiotherapy, relapse, risk stratification, staging, Wilm's tumor, Author(s): Yogesh Kumar Sarin (corresponding author) [1]; Pute U. Losu [1]; Anita Nangia [2] INTRODUCTION The last few decades have seen remarkable progress in the outcome and management of Wilms' [...]

Published
2024
Full Text
View/download PDF

3. RESHAPING TREATMENT PARADIGMS: Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry's pipeline remains flush with many late-stage therapies showing promising data and transformative potential

Author

Fernando, Surani

Subjects
Merck & Company Inc., Johnson & Johnson, Credit Suisse Group AG, Novo Nordisk A/S, Eli Lilly and Co., Sanofi S.A., Hemlibra (Medication), Tremfya (Medication), Financial services industry, Ezetimibe, Sitagliptin, Guselkumab, Brand equity, Type 2 diabetes, Patient compliance, Tafamidis, Financial services, Pharmaceutical industry, Biological products industry, Semaglutide
Abstract

* As another U.S. election approaches and uncertainty looms over the biopharma world, the horizon remains bright with late-stage therapies showing promising results and transformative potential. Amid the evolving landscape, [...]

Published
2024

4. Questions and Answers About Clozapine, Part 2: A Dialogue About Indications for Clozapine, Managing Adverse Effects, and More

Author

Meyer, Jonathan M.

Subjects
United States. Food and Drug Administration -- Management, Linaclotide -- Complications and side effects, Patient compliance, Questions and answers, Type 2 diabetes -- Complications and side effects, Clozapine -- Complications and side effects, Evidence-based medicine, Armodafinil -- Complications and side effects, Health, Psychology and mental health, Company business management, Management, Complications and side effects
Abstract

An important concept in managing clozapine's clinical issues and adverse effects is that not all approaches possess the highest levels of evidence from randomized clinical trials (RCTs), leaving clinicians to [...]

Published
2024

5. REFRAMING APPROACHES TO SCHIZOPHRENIA

Author

Weiden, Peter J.

Subjects
United States. Food and Drug Administration, Trospium, Patient compliance, Schizophrenia -- Care and treatment, Evidence-based medicine, Haloperidol, Health, Psychology and mental health, Care and treatment
Abstract

I began my career when the major treatments for schizophrenia were haloperidol and chlorpromazine. Since then, treatments for schizophrenia have improved slowly and incrementally, especially when looking back in the [...]

Published
2024

6. Questions and Answers About Clozapine: A Dialogue About the Use of Plasma Levels

Author

Meyer, Jonathan M.

Subjects
Patient compliance, Schizophrenia, Questions and answers, Clozapine, Health, Psychology and mental health
Abstract

Clozapine remains the only effective medication for treatment-resistant schizophrenia (TRS), with response rates [greater than or equal to] 40% in controlled trials, compared with < 5% for other antipsychotics, and [...]

Published
2024

7. Development of Mini-Tablet and Multi-Unit Pellet Systems: Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles

Author

Challener, Cynthia A.

Subjects
Patient compliance, Drug therapy, Combination, Coatings -- Product introduction, Business, Pharmaceuticals and cosmetics industries
Abstract

Multi-unit pellet systems (MUPS) and intelligently encapsulated mini-tablet systems (EMTS) have unique combinations of advantages compared to conventional oral formulations. The drug release from MUPS and EMTS can be modified [...]

Published
2024

8. Unleashing Their Potential: The Evolving Landscape of DHTs: Key considerations in deploying fit-for-purpose digital health technologies

Subjects
Thermo Fisher Scientific Inc., Medical research, Medicine, Experimental, Scientific equipment and supplies industry, Usability testing, Patient compliance, General interest, Health
Abstract

Jill Sommerville Senior Director Lauren Flood Associate Director Matthew Ryan Associate Director All with the digital and decentralized solutions for the PPD clinical research business of Thermo Fisher Scientific It's [...]

Published
2024

9. Longitudinal adherence to surveillance for late effects of cancer treatment: a population-based study of adult survivors of childhood cancer

Author

Shuldiner, Jennifer, Sutradhar, Rinku, Lau, Cindy, Shah, Nida, Lam, Emily, Ivers, Noah, and Nathan, Paul C.

Subjects
Oncology, Experimental, Patient compliance, Colorectal cancer -- Drug therapy -- Risk factors, Cancer -- Care and treatment -- Research, Adults, Cancer in children -- Risk factors -- Drug therapy, Health
Abstract

Background: Adult survivors of childhood cancer are at elevated risk of morbidity and mortality compared to the general population, but their adherence to lifelong periodic surveillance is suboptimal. We aimed to examine adherence to surveillance guidelines for high-yield tests and identify risk factors for nonadherence in adult survivors of childhood cancer. Methods: In this retrospective, population-based cohort study, we used health care administrative data from Ontario, Canada, to identify adult survivors of childhood cancer diagnosed between 1986 and 2014 who were at elevated risk of therapy-related colorectal cancer, breast cancer, or cardiomyopathy. Using a Poisson regression framework, we assessed longitudinal adherence and predictors of adherence to the Children's Oncology Group surveillance guideline. Results: Among 3241 survivors, 327 (10%), 234 (7%), and 3205 (99%) were at elevated risk for colorectal cancer, breast cancer, and cardiomyopathy, respectively. Within these cohorts, only 13%, 6%, and 53% were adherent to recommended surveillance as of February 2020. During a median follow-up of 7.8 years, the proportion of time spent adherent was 14% among survivors at elevated risk for colorectal cancer, 10% for breast cancer, and 43% for cardiomyopathy. Significant predictors of adherence varied across the risk groups, but higher comorbidity was associated with adherence to recommended surveillance. Interpretation: Survivors of childhood cancer in Ontario are rarely up to date for recommended surveillance tests. Tailored interventions beyond specialized clinics are needed to improve surveillance adherence., Adult survivors of childhood cancer are at elevated risk of late morbidity and premature mortality ('late effects'), resulting from their treatment. (1) As many as 80% of childhood cancer survivors [...]

Published
2024
Full Text
View/download PDF

10. THE FINE ART OF DRUG FORMULATION

Author

Watts, Gary

Subjects
Patient compliance, Drug discovery, Drugs -- Evaluation, Business, Chemicals, plastics and rubber industries, Engineering and manufacturing industries, Business, international
Abstract

When it comes to pharmaceuticals, formulation development is like a finely tuned art form; the scientific understanding of a drug's intrinsic properties must be balanced with the practical challenges of [...]

Published
2024

11. Reshaping Dosage Forms: Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed

Author

Haigney, Susan

Subjects
Health care reform, Patient compliance, Drugs -- Dosage and administration -- Innovations, Vaccines -- Innovations -- Dosage and administration, Pharmacogenetics, Business, Pharmaceuticals and cosmetics industries
Abstract

The landscape of treatment for medical conditions and illnesses has become tailored and rich thanks to advances in personalized medicine, artificial intelligence (AI), and emerging modalities. Cell and gene therapies [...]

Published
2024

12. Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Author

Patel, Gayatri and Patel, Divyangi

Subjects
Medical research, Medicine, Experimental, Patient compliance, Ion exchange resins, Doxylamine, Cefpodoxime, Business, Pharmaceuticals and cosmetics industries
Abstract

Cefpodoxime proxetil (CFPD PRXL) is a third-generation cephalosporin antibiotic with broad-spectrum activity. However, its bitter taste often leads to poor patient compliance. This study aimed to develop a taste-masked drug [...]

Published
2024

13. EFFECT OF FOOD-BASED NUTRITION INTERVENTION ON MANAGEMENT OF NON-COMMUNICABLE DISEASES AMONG PEOPLE LIVING WITH HIV IN BUSIA COUNTY HOSPITAL, KENYA

Author

Akelola, R., Wamukoya, E., and Situma, J.

Subjects
Heart diseases -- Control, HIV (Viruses) -- Control, Medical research, Medicine, Experimental, Patient compliance, Porridge -- Health aspects, Highly active antiretroviral therapy, Medical nutrition therapy -- Methods, Agricultural industry, Food/cooking/nutrition, Health
Abstract

Good nutrition optimizes benefits of ART (Antiretroviral therapy) and increases treatment adherence, both prolongs lives of PLHIV (NASCOP, 2014), without proper care and management it exposes them to non-communicable diseases (NCDs). Key objective; to determine the effect of food-based nutrition intervention on the management of NCDs among PLHIV in Busia. The design was experimental using randomized control trial approach. The control group had 30 subjects who were fed on Plumpy'nut while treatment group had 30 subjects who were fed on Power Porridge (PROLCARMIV), for 60 days. Subjects were purposively selected from the Comprehensive Care Clinic (CCC) in Busia County referral hospital- Kenya, further study subjects were randomly selected using simple random sampling, assigned equally to each group. Data were collected using a structured questionnaire analyzed using Social Package for Statistical Sciences version 26. Prevalence of NCDS; 75.5% hypertension; 15.6% diabetes and 8.9% heart disease; post-intervention BMI for intervention group increased; laboratory analyses; Hb post--intervention results; mean levels were higher in intervention group (M=13.62, SD=2.69) p-value = 0.487 compared to control group (12.69, SD=1.24), p value= 0.471. Random Blood Sugar (RBS) were higher in control group (5.96, SD=1.70), with p value= Key words: Food-Based Nutrition Intervention, HIV, NCDs, PLHIV, PROLCARMIV, Power Porridge, INTRODUCTION Non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from an NCD before age 70; 86% [...]

Published
2024
Full Text
View/download PDF

14. Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021

Author

Nsengiyumva, Ntwali Placide, Khan, Amera, Gler, Maricelle Ma. Tarcela S., Tonquin, Mariecef L., Marcelo, Danaida, Andrews, Mark C., Duverger, Karine, Ahmed, Shahriar, Ibrahim, Tasmia, Banu, Sayera, Sultana, Sonia, Morales, Mona Lisa, Villanueva, Andre, Efo, Egwumo, Onjare, Baraka, Celan, Cristina, and Schwartzman, Kevin

Subjects
Medical care, Cost of, Patient compliance, Drug resistance, Tuberculosis, Health, Stop TB Partnership, World Health Organization
Abstract

As part of the mission to cure and ultimately eliminate tuberculosis (TB), maintaining treatment adherence poses a substantial barrier (1). Persons with TB must complete multidrug regimens typically lasting [greater [...]

Published
2024
Full Text
View/download PDF

15. TECHNOLOGY REMOTE PATIENT MONITORING

Subjects
Patient compliance, Business, Economics, Health care industry
Abstract

Closing gaps in care with remote patient monitoring Editor's Note: The content in this piece is client sponsored. In the ever-evolving health care landscape, closing gaps in care and keeping [...]

Published
2023

16. 3 Things You Should Know About Glaucoma Causes and Treatment

Subjects
Education grants, Patient compliance, Glaucoma -- Drug therapy, Health
Abstract

Release Date: August 1, 2024 Expiration Date: August 1, 2025 Learning Objectives Upon successful completion of this activity, you should be better prepared to: * Outline the pathophysiology of ocular [...]

Published
2024

17. 3 Things You Should Know About the Latest in nAMD and DME Treatment

Subjects
Genentech Inc., Medical research, Medicine, Experimental, Patient compliance, Biotechnology industry, Ophthalmology, College teachers, Health
Abstract

Murtaza Adam, MD Partner Physician Chair, Clinical Research Committee Colorado Retina Associates Adjunct Clinical Associate Professor Rocky Vista University Denver, CO Disclosures: Consultant: Genentech, Regeneron, Regenxbio; Speakers' Bureau: Apellis Pharmaceuticals, [...]

Published
2024

19. PDTs represent a shift in how treatment is delivered: Through the use of data and improved patient engagement, prescription digital therapeutics offer the potential for better care coordination and patient outcomes

Subjects
Homeopathy -- Materia medica and therapeutics, Patient compliance, Health care industry, Therapeutics -- Evaluation, Evidence-based medicine, Health care industry, Business
Abstract

Prescription digital therapeutics (PDTs) are part of a broader category of digital health products that may be used for lifestyle, wellness and other health-related purposes. However, the difference is that [...]

Published
2024

20. Research Findings from Surat Municipal Institute of Medical Education and Research Update Understanding of Type 2 Diabetes [Unlocking the potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in revolutionizing type 2 diabetes ...]

Subjects
Patient compliance, Medical personnel -- Training, Type 2 diabetes, Liraglutide, Physical fitness, Glucagon, Health
Abstract

2024 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on type 2 diabetes have been published. According to [...]

Published
2024

21. BioSurfaces receives $2.06 million grant from Bill & Melinda Gates Foundation to advance development of BSCC device

Subjects
Medical research, Medicine, Experimental, Patient compliance, Genetic engineering, Genetically modified organisms, Company financing, Pharmaceuticals and cosmetics industries
Abstract

BioSurfaces, a company focused on improving lives throughout the world, announced that the company has been awarded a $2.06 million grant from the Bill & Melinda Gates Foundation. This one-year [...]

Published
2024

22. Pfizer's Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors

Subjects
Pfizer Inc., Patient compliance, Prothrombin complex concentrate, Hemophilia -- Drug therapy, Drug approval, Teenagers, Youth, Marketing, Blood coagulation factor VIII, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older [...]

Published
2024

23. TAHO Pharma begins patient dosing in US phase III trial of antithrombotic oral dissolving film, TAH3311

Subjects
United States. Food and Drug Administration, Stroke (Disease), Patient compliance, Clinical trials, Apixaban -- Product development, Pharmaceuticals and cosmetics industries
Abstract

TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its US phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In [...]

Published
2024

24. Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial

Subjects
Boston Scientific Corp. -- Product development, Medical test kit industry -- Product development, Patient compliance, Anticoagulants (Medicine), Atrial fibrillation -- Risk factors, Medical equipment and supplies industry -- Product development, Clinical trials, Pharmaceuticals and cosmetics industries
Abstract

Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. Key findings from the study [...]

Published
2024

26. Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions

Subjects
United States. Food and Drug Administration, Tasigna (Medication), Patient compliance, Nilotinib, Drug approval, Antineoplastic agents, Antimitotic agents
Abstract

Azurity Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed [...]

Published
2024

27. Research Results from University of Kinshasa Update Understanding of Malaria (Adherence to national malaria treatment guidelines: A retrospective study among healthcare workers in community pharmacies, Kinshasa, Democratic Republic of the Congo)

Subjects
Patient compliance, Physical fitness, Medical personnel
Abstract

2024 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on malaria are discussed in a new report. According to [...]

Published
2024

30. New Colon Cancer Data Have Been Reported by Researchers at Medical University of Lodz (The Impact of Preoperative and Postoperative Nutritional Interventions on Treatment Outcomes and Quality of Life in Colorectal Cancer Patients-A ...)

Subjects
Oncology, Experimental, Cancer patients -- Prognosis -- Care and treatment -- Patient outcomes, Patient compliance, Colorectal cancer -- Patient outcomes -- Prognosis -- Care and treatment, Cancer -- Research, Physical fitness
Abstract

2024 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on colon cancer have been published. According to news [...]

Published
2024

31. Surescripts Enhances Visibility into Patient Medication Histories for Health Plans

Subjects
Patients -- Care and treatment, Patient compliance, Health insurance, Arts and entertainment industries
Abstract

Surescripts, a health information network, reported it is expanding its Medication History for Populations solution to health plans to better support patient care, improve medication adherence and lower costs. Surescripts [...]

Published
2024

32. Daily dose

Subjects
Medication errors, Patient compliance
Abstract

GOOD TO KNOW Daily dose Simplify medication management with an automatic pill dispenser your gadgets If you're looking to enhance your medication management routine, automatic pill dispensers are a great [...]

Published
2024

36. 5 tips for breast cancer survivors to navigate mental health during treatment

Subjects
Cancer survivors, Patient compliance, Mental health, Anxiety, Breast cancer, Stress (Psychology), Health
Abstract

Breast cancer is a formidable adversary, challenging not only the body but also the mind and spirit of those who face it. The journey from diagnosis through treatment and beyond [...]

Published
2024

37. Shields Health Solutions and Sutter Health Bolster Collaboration

Subjects
Walgreen Co., Rheumatoid factor, Patient compliance, Drugstores, Pharmacy, Arts and entertainment industries, Sutter Health
Abstract

Shields Health Solutions, a specialty pharmacy accelerator in the United States and a Walgreens-owned company, has expanded its work with Sutter Health, a not-for-profit health systems in the U.S., to [...]

Published
2024

42. New Data from Heart Institute Illuminate Research in Obesity (A Randomized Controlled Trial Comparing Loss versus Gain Incentives to Improve Adherence to an Obesity Treatment Intervention in Adolescents)

Subjects
Pediatrics, Obesity in adolescence -- Drug therapy, Patient compliance, Obesity in children -- Drug therapy, Children -- Health aspects, Physical fitness, Health
Abstract

2024 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on obesity have been presented. According to news originating from [...]

Published
2024

44. LakeShore`s YSJA rabies vaccine receives approval for Phase III trial in China

Subjects
Biological products industry -- Product development, Vaccination, Patient compliance, Clinical trials, Vaccines -- Product development, Rabies, Business, News, opinion and commentary
Abstract

LakeShore Biopharma announced that it has been granted approval for a Phase III clinical trial by the National Medical Products Administration, or NMPA, in China to explore the immunogenicity and [...]

Published
2024

45. Bayer & Regeneron present long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in DME confirmed at three years at AAO meeting

Subjects
Bayer AG, Medical research, Medicine, Experimental, Patient compliance, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, Eylea (Medication)
Abstract

Bayer and its collaboration partner Regeneron presented results from the open-label extension study of the clinical trial PHOTON in patients with diabetic macular edema (DME) at three years, in a [...]

Published
2024

46. Patent Issued for Wearable micro-dosing drug delivery device (USPTO 12097352)

Subjects
Insulet Corp. -- Intellectual property, Drugs -- Vehicles, Medical test kit industry -- Intellectual property, Patient compliance, Medical equipment and supplies industry -- Intellectual property, Type 2 diabetes, Drug delivery systems -- Intellectual property, Physical fitness, Health
Abstract

2024 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent by the inventors Alles, Matthew (Winchester, MA, US), Brodeur, Craig [...]

Published
2024

47. Investigators from Federal University Ceara Have Reported New Data on Chagas Disease (Causality and Severity of Adverse Reactions and Biochemical Changes To Benznidazole Treatment In Patients With Chronic Chagas Disease)

Subjects
Medical research, Medicine, Experimental, Patient compliance, Parasitic diseases -- Complications and side effects -- Care and treatment, Chagas' disease -- Care and treatment -- Complications and side effects, Physical fitness, Health
Abstract

2024 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Parasitic Diseases and Conditions - Chagas Disease is [...]

Published
2024

48. Bayer submits marketing authorization application to EMA for elinzanetant to treat moderate to severe vasomotor symptoms

Subjects
Bayer AG -- Marketing, Patient compliance, Menopause, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Berlin Bayer has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known [...]

Published
2024

49. Reports from Anand Pharmacy College Describe Recent Advances in Nanobiotechnology [Multichannel 3D-printed bionanoparticles-loaded tablet (M3DPBT): designing, development, and in vitro functionality assessment]

Subjects
3D printing, Patient compliance, Drugstores, Pharmacy, Physical fitness, Health
Abstract

2024 OCT 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on nanobiotechnology. According to news reporting from Anand [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results